Association of Bezafibrate Treatment With Reduced Risk of Cancer in Patients With Coronary Artery Disease.

[1]  J. Lan,et al.  Synergy between peroxisome proliferator‐activated receptor γ agonist and radiotherapy in cancer , 2018, Cancer science.

[2]  Alexander S. Banks,et al.  Noncanonical agonist PPARγ ligands modulate the response to DNA damage and sensitize cancer cells to cytotoxic chemotherapy , 2018, Proceedings of the National Academy of Sciences.

[3]  R. Collins,et al.  Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial , 2017, The Lancet.

[4]  M. Hao,et al.  Evasion of immunosurveillance by genomic alterations of PPARγ/RXRα in bladder cancer , 2017, Nature Communications.

[5]  G. Weisz,et al.  Associated Risk of Malignancy in Patients with Cardiovascular Disease: Evidence and Possible Mechanism. , 2017, The American journal of medicine.

[6]  J. Hansen,et al.  Myocardial infarction and future risk of cancer in the general population—the Tromsø Study , 2017, European Journal of Epidemiology.

[7]  A. Guerrero,et al.  2015 Clinical Practice Guidelines for the Management of Dyslipidemia in the Philippines - Executive Summary , 2016, ASEAN heart journal : Official journal of the ASEAN Federation of Cardiology.

[8]  A. S. Laganà,et al.  Pleiotropic Actions of Peroxisome Proliferator-Activated Receptors (PPARs) in Dysregulated Metabolic Homeostasis, Inflammation and Cancer: Current Evidence and Future Perspectives , 2016, International journal of molecular sciences.

[9]  B. Baradaran,et al.  Peroxisome Proliferator‐Activated Receptor Ligands and Their Role in Chronic Myeloid Leukemia: Therapeutic Strategies , 2016, Chemical biology & drug design.

[10]  A. Tenenbaum,et al.  Elevated Triglyceride Level Is Independently Associated With Increased All-Cause Mortality in Patients With Established Coronary Heart Disease: Twenty-Two–Year Follow-Up of the Bezafibrate Infarction Prevention Study and Registry , 2016, Circulation. Cardiovascular quality and outcomes.

[11]  Kyoko Omori,et al.  Bezafibrate, a peroxisome proliferator-activated receptor α agonist, decreases circulating CD14(+)CD16(+) monocytes in patients with type 2 diabetes. , 2015, Translational research : the journal of laboratory and clinical medicine.

[12]  J. Cerhan,et al.  Heart Failure After Myocardial Infarction Is Associated With Increased Risk of Cancer. , 2014, Journal of the American College of Cardiology.

[13]  F. Khanim,et al.  Bezafibrate and medroxyprogesterone acetate in resistant and relapsed endemic Burkitt lymphoma in Malawi; an open‐label, single‐arm, phase 2 study (ISRCTN34303497) , 2014, British journal of haematology.

[14]  Timothy J Nelson,et al.  Patients with heart failure have an increased risk of incident cancer. , 2013, Journal of the American College of Cardiology.

[15]  A. Keech,et al.  Therapeutic Effects of PPARα Agonists on Diabetic Retinopathy in Type 1 Diabetes Models , 2012, Diabetes.

[16]  S. Bonovas,et al.  Use of Fibrates and Cancer Risk: A Systematic Review and Meta-Analysis of 17 Long-Term Randomized Placebo-Controlled Trials , 2012, PloS one.

[17]  A. Buchs,et al.  Incidence of malignancies in patients with diabetes mellitus and correlation with treatment modalities in a large Israeli health maintenance organization: a historical cohort study. , 2011, Metabolism: clinical and experimental.

[18]  J. Tu,et al.  Use of fibrates in the United States and Canada. , 2011, JAMA.

[19]  J. A. Murray,et al.  Combined bezafibrate and medroxyprogesterone acetate have efficacy without haematological toxicity in elderly and relapsed acute myeloid leukaemia (AML) , 2010, British journal of haematology.

[20]  J. A. Murray,et al.  Combined Bezafibrate and Medroxyprogesterone Acetate: Potential Novel Therapy for Acute Myeloid Leukaemia , 2009, PloS one.

[21]  D. Arveiler,et al.  Ten-year all-cause mortality in presumably healthy subjects on lipid-lowering drugs (from the Prospective Epidemiological Study of Myocardial Infarction [PRIME] prospective cohort). , 2009, The American journal of cardiology.

[22]  D. Tanné,et al.  Does the lipid-lowering peroxisome proliferator-activated receptors ligand bezafibrate prevent colon cancer in patients with coronary artery disease? , 2008, Cardiovascular diabetology.

[23]  U. Goldbourt,et al.  Secondary prevention with bezafibrate therapy for the treatment of dyslipidemia: an extended follow-up of the BIP trial. , 2008, Journal of the American College of Cardiology.

[24]  Sui Huang,et al.  PPARα agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition , 2008, Proceedings of the National Academy of Sciences.

[25]  M. Aller,et al.  The use of inflammation by tumor cells , 2005, Cancer.

[26]  Z. Serdar,et al.  The effect of fenofibrate on serum paraoxonase activity and inflammatory markers in patients with combined hyperlipidemia. , 2005, Kardiologia polska.

[27]  D. Tanné,et al.  Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. , 2005, Archives of internal medicine.

[28]  S. Karpatkin,et al.  Hypercoagulability preceding cancer , 2005 .

[29]  G. J. Miller,et al.  Increased incidence of neoplasia of the digestive tract in men with persistent activation of the coagulant pathway , 2004, Journal of thrombosis and haemostasis : JTH.

[30]  D. Mikhailidis,et al.  Effect of Fenofibrate on Serum Inflammatory Markers in Patients With High Triglyceride Values , 2004 .

[31]  P. Simpson‐Haidaris,et al.  Matrix-fibrinogen enhances wound closure by increasing both cell proliferation and migration. , 2003, Blood.

[32]  C. Lewis,et al.  The role of fibrinogen and related fragments in tumour angiogenesis and metastasis , 2003, Expert opinion on biological therapy.

[33]  T. Noda,et al.  Concomitant suppression of hyperlipidemia and intestinal polyp formation in Apc-deficient mice by peroxisome proliferator-activated receptor ligands. , 2003, Cancer research.

[34]  C. Bunce,et al.  Fibrates and medroxyprogesterone acetate induce apoptosis of primary Burkitt's lymphoma cells and cell lines: potential for applying old drugs to a new disease , 2003, Leukemia.

[35]  D. Mikhailidis,et al.  Effect of Ciprofibrate on C-Reactive Protein and Fibrinogen Levels , 2002, Angiology.

[36]  B. Rybarczyk,et al.  Tumors and Fibrinogen , 2001, Annals of the New York Academy of Sciences.

[37]  B. Modan,et al.  Selectively increased risk of cancer in men with coronary heart disease. , 2001, The American journal of cardiology.

[38]  Bezafibrate Infarction Prevention study.  Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. , 2000, Circulation.

[39]  J. Herbert,et al.  Effect of ciprofibrate on fibrinogen synthesis in vitro on hepatoma cells and in vivo in genetically obese Zucker rats. , 1999, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[40]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[41]  A. Gugliandolo,et al.  Effect of Three Fibrate Derivatives and of Two HMG-CoA Reductase Inhibitors on Plasma Fibrinogen Level in Patients with Primary Hypercholesterolemia , 1993, Thrombosis and Haemostasis.

[42]  M. Karvonen,et al.  A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. , 1979, British heart journal.

[43]  R. Kornowski,et al.  Long-term outcomes after percutaneous coronary interventions in cancer survivors , 2017, Coronary artery disease.

[44]  M. Pencina,et al.  Head-to-head comparison of statins versus fibrates in reducing plasma fibrinogen concentrations: A systematic review and meta-analysis. , 2016, Pharmacological research.

[45]  P. J. Loehrer.  Statins and Cancer Risk: A Meta-analysis , 2007 .

[46]  J. Berger,et al.  The mechanisms of action of PPARs. , 2002, Annual review of medicine.

[47]  B. Balkau,et al.  A pharmacoepidemiological assessment of the effect of statins and fibrates on fibrinogen concentration. , 2002, Atherosclerosis.

[48]  L. Dublin.  Vital Statistics. , 1961, British medical journal.

[49]  T. Kooistra,et al.  HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY Fibrates Suppress Fibrinogen Gene Expression in Rodents Via Activation of the Peroxisome Proliferator-Activated Receptor- a , 2022 .

[50]  D.,et al.  Regression Models and Life-Tables , 2022 .